Global Inclusion & Diversity - Bristol Myers Squibb

Global Inclusion & Diversity  Bristol Myers Squibb

BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study - BioSpace

BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study  BioSpace

For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been...

For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been  FiercePharma

BMS cafeteria.jpeg - East Oregonian

BMS cafeteria.jpeg  East Oregonian

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma - OncLive

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma  OncLive

BMS basketball tryouts scheduled for October 21-23 - WBIW.com

BMS basketball tryouts scheduled for October 21-23  WBIW.com

Our impact - Bristol Myers Squibb

Our impact  Bristol Myers Squibb

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline  BioSpace

BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing -...

BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing  FiercePharma

How BMS employees champion STEM education & diversity - Bristol Myers Squibb

How BMS employees champion STEM education & diversity  Bristol Myers Squibb

The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia - BioSpace

The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia  BioSpace

Get help paying for your medicines - Bristol Myers Squibb

Get help paying for your medicines  Bristol Myers Squibb

Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition - BioSpace

Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition  BioSpace

Our science - Bristol Myers Squibb

Our science  Bristol Myers Squibb

BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134 - BioSpace

BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134  BioSpace

Pharmaceutical business development - Bristol Myers Squibb

Pharmaceutical business development  Bristol Myers Squibb

Global Patient Week 2024 - Bristol Myers Squibb

Global Patient Week 2024  Bristol Myers Squibb

Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb

Science Firsthand: Translating the promise of cell therapy  Bristol Myers Squibb

Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) - Bristol Mye...

Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS)  Bristol Myers Squibb

Independent research - Bristol Myers Squibb

Independent research  Bristol Myers Squibb

BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipelin...

BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline  Fierce Biotech

FDA Approves First Novel Schizophrenia Drug in 35 Years - BioSpace

FDA Approves First Novel Schizophrenia Drug in 35 Years  BioSpace

Global Inclusion & Diversity Report - Bristol Myers Squibb

Global Inclusion & Diversity Report  Bristol Myers Squibb

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline - Genetic Engineering & ...

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline  Genetic Engineering & Biotechnology News

Our company: Industry leadership in BioPharma - Bristol Myers Squibb

Our company: Industry leadership in BioPharma  Bristol Myers Squibb

Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on - Fierce...

Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on  FiercePharma

ASPIRE: Our commitment to address health inequities in low- and middle-income countries - Bristol...

ASPIRE: Our commitment to address health inequities in low- and middle-income countries  Bristol Myers Squibb

Become a business supplier - Bristol Myers Squibb

Become a business supplier  Bristol Myers Squibb

Clinical trials & studies - Bristol Myers Squibb

Clinical trials & studies  Bristol Myers Squibb

Professional Service Automation Software for IT Professionals | Kaseya BMS - Kaseya

Professional Service Automation Software for IT Professionals | Kaseya BMS  Kaseya

Transparency & reporting - Bristol Myers Squibb

Transparency & reporting  Bristol Myers Squibb

Veterans Day Community Tribute at Chelsea Senior Center - thesuntimesnews.com

Veterans Day Community Tribute at Chelsea Senior Center  thesuntimesnews.com

Working at BMS - Bristol Myers Squibb

Working at BMS  Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Th...

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma  Bristol Myers Squibb - News

Immunology patient resources - Bristol Myers Squibb

Immunology patient resources  Bristol Myers Squibb

5 Schizophrenia Candidates Chasing BMS’ KarXT - BioSpace

5 Schizophrenia Candidates Chasing BMS’ KarXT  BioSpace

Early innovation at BMS - Bristol Myers Squibb

Early innovation at BMS  Bristol Myers Squibb

Carlos' Inspiring Journey of Overcoming Schizophrenia - Bristol Myers Squibb

Carlos' Inspiring Journey of Overcoming Schizophrenia  Bristol Myers Squibb

A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead - Clinical Trials Arena

A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead  Clinical Trials Arena

BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC - BioSpace

BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC  BioSpace

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC - OncLive

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC  OncLive

People and business resource groups - Bristol Myers Squibb

People and business resource groups  Bristol Myers Squibb

Research to Help Replace Medication Infusions with Quick Injections to Launch on SpaceX CRS-27 - ...

Research to Help Replace Medication Infusions with Quick Injections to Launch on SpaceX CRS-27  ISS National Lab

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $...

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research  Bristol Myers Squibb - News

Advances in the Science of Immune-Mediated Diseases Treatment - Bristol Myers Squibb

Advances in the Science of Immune-Mediated Diseases Treatment  Bristol Myers Squibb

BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years - BioSpace

BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years  BioSpace

Psoriasis around the world - Bristol Myers Squibb

Psoriasis around the world  Bristol Myers Squibb

ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer fiel...

ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field  FiercePharma

Breaking barriers: SOGIIS data collection for improved health equity in clinical trials - Bristol...

Breaking barriers: SOGIIS data collection for improved health equity in clinical trials  Bristol Myers Squibb

Survivorship Today: Cancer survivor stories - Bristol Myers Squibb

Survivorship Today: Cancer survivor stories  Bristol Myers Squibb

Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...

Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it?  Bristol Myers Squibb

Our leadership - Bristol Myers Squibb

Our leadership  Bristol Myers Squibb

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Coben...

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy  FiercePharma

Equipping providers in underserved communities to improve lung cancer care - Bristol Myers Squibb

Equipping providers in underserved communities to improve lung cancer care  Bristol Myers Squibb

Continuing Innovations on TYK2 Inhibition - Bristol Myers Squibb

Continuing Innovations on TYK2 Inhibition  Bristol Myers Squibb

Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval - BioSpace

Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval  BioSpace

BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval - FiercePharma

BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval  FiercePharma

BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody - BioSpace

BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody  BioSpace

Getting to the heart of hypertrophic cardiomyopathy (HCM): The power of the global patient voice ...

Getting to the heart of hypertrophic cardiomyopathy (HCM): The power of the global patient voice  Bristol Myers Squibb

Business development leadership team - Bristol Myers Squibb

Business development leadership team  Bristol Myers Squibb

Worldwide locations - Bristol Myers Squibb

Worldwide locations  Bristol Myers Squibb

Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends - BioSpace

Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends  BioSpace

Celebrating four years of patient engagement through PEER program - Bristol Myers Squibb

Celebrating four years of patient engagement through PEER program  Bristol Myers Squibb

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administrat...

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma  Bristol Myers Squibb - News

Building a better future: Bristol Myers Squibb 2023 ESG report - Bristol Myers Squibb

Building a better future: Bristol Myers Squibb 2023 ESG report  Bristol Myers Squibb

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Ha...

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign  Bristol Myers Squibb - News

Lockton Re raids BMS Re North Carolina office for quartet of brokers - Re-Insurance.com

Lockton Re raids BMS Re North Carolina office for quartet of brokers  Re-Insurance.com

Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research - Bristol Myers Squibb

Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research  Bristol Myers Squibb

BMS, Pfizer, Regeneron, Cardinal Health and more back 'enhanced' thrombosis awareness campaign - ...

BMS, Pfizer, Regeneron, Cardinal Health and more back 'enhanced' thrombosis awareness campaign  FiercePharma

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for ...

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)  Bristol Myers Squibb - News

FDA Action Alert: BMS, Merck, Sanofi/Regeneron and More - BioSpace

FDA Action Alert: BMS, Merck, Sanofi/Regeneron and More  BioSpace

BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues - BioSpace

BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues  BioSpace

Performance of ADI Wireless BMS Ensured Using Record and Playback Solution - Electronic Design

Performance of ADI Wireless BMS Ensured Using Record and Playback Solution  Electronic Design

Spreading eosinophilic esophagitis awareness and wellness in patients - Bristol Myers Squibb

Spreading eosinophilic esophagitis awareness and wellness in patients  Bristol Myers Squibb

AI-driven protein degradation research reshaping drug discovery - Bristol Myers Squibb

AI-driven protein degradation research reshaping drug discovery  Bristol Myers Squibb

Kevin’s story on navigating life with eosinophilic esophagitis - Bristol Myers Squibb

Kevin’s story on navigating life with eosinophilic esophagitis  Bristol Myers Squibb

Building on Today’s Science to Research Medicines of Tomorrow - Bristol Myers Squibb

Building on Today’s Science to Research Medicines of Tomorrow  Bristol Myers Squibb

Compañía Biofarmacéutica Global - Bristol Myers Squibb

Compañía Biofarmacéutica Global  Bristol Myers Squibb

Working together to advance research in liver disease - Bristol Myers Squibb

Working together to advance research in liver disease  Bristol Myers Squibb

BMS Re welcomes Aon’s Brad Melvin as President and CEO, US - Reinsurance News

BMS Re welcomes Aon’s Brad Melvin as President and CEO, US  Reinsurance News

Exploring New Treatment Options for Pulmonary Fibrosis - Bristol Myers Squibb

Exploring New Treatment Options for Pulmonary Fibrosis  Bristol Myers Squibb

Driving cutting-edge research for treating blood disorders - Bristol Myers Squibb

Driving cutting-edge research for treating blood disorders  Bristol Myers Squibb

BMS analytics head Conrad leaving as ProLink defections also continue - Re-Insurance.com

BMS analytics head Conrad leaving as ProLink defections also continue  Re-Insurance.com

Early Treatment for Rheumatoid Arthritis - Bristol Myers Squibb

Early Treatment for Rheumatoid Arthritis  Bristol Myers Squibb

Advancing oncology care: The potential of subcutaneous immunotherapy - Bristol Myers Squibb

Advancing oncology care: The potential of subcutaneous immunotherapy  Bristol Myers Squibb

BMS Re US hires Aon’s regional insurer group president Melvin as next CEO - Re-Insurance.com

BMS Re US hires Aon’s regional insurer group president Melvin as next CEO  Re-Insurance.com

Chris Boerner, PhD - Bristol Myers Squibb

Chris Boerner, PhD  Bristol Myers Squibb

Exploring the tumor microenvironment - Bristol Myers Squibb

Exploring the tumor microenvironment  Bristol Myers Squibb

Improving health literacy through Universal Patient Language program - Bristol Myers Squibb

Improving health literacy through Universal Patient Language program  Bristol Myers Squibb

BMS CAR-T Therapy Wins FDA Approval for Expanded Use in Follicular Lymphoma - BioSpace

BMS CAR-T Therapy Wins FDA Approval for Expanded Use in Follicular Lymphoma  BioSpace

Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb

Bringing the science of cell therapy into autoimmune diseases  Bristol Myers Squibb

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific - Fierce Biotech

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific  Fierce Biotech

BMS named one of America's Most JUST companies - Bristol Myers Squibb

BMS named one of America's Most JUST companies  Bristol Myers Squibb

Doing R&D “Differently” to Transform Treatment for Serious Diseases - Bristol Myers Squibb

Doing R&D “Differently” to Transform Treatment for Serious Diseases  Bristol Myers Squibb

BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial - Clinical Trials Arena

BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial  Clinical Trials Arena

JJ Johnson to leave BMS Re - Re-Insurance.com

JJ Johnson to leave BMS Re  Re-Insurance.com

Researching Lung Cancer Treatments to Give More Patients Better Outcomes - Bristol Myers Squibb

Researching Lung Cancer Treatments to Give More Patients Better Outcomes  Bristol Myers Squibb

Encouraging the next generation to pursue STEM education - Bristol Myers Squibb

Encouraging the next generation to pursue STEM education  Bristol Myers Squibb

Advancing lupus research to address unmet needs - Bristol Myers Squibb

Advancing lupus research to address unmet needs  Bristol Myers Squibb